tebnow
Clinical Research/The Lancet/1d ago

Supporting Early-Career Clinicians Amidst Workforce Challenges

The initial years of medical practice and research are critical for developing expertise and professional identity among early-career clinicians and academics. However, these formative years are increasingly fraught with challenges, including workforce pressures, staffing shortages, and funding constraints. Such conditions can hinder the growth and confidence of new professionals in the healthcare field. As universities and healthcare systems face mounting demands, it is essential to address these issues to ensure that early-career individuals receive the support they need to thrive. The healthcare community must prioritize initiatives that bolster the development of these professionals, ensuring a robust future workforce capable of meeting the evolving needs of patients and the healthcare system.

early-career / medical education / workforce challenges / healthcare professionals / support initiatives

Health Tech

All →

CVS Caremark Settles with FTC, Promises Changes to Insulin Pricing Practices

CVS Health's Caremark has reached a significant settlement with the Federal Trade Commission (FTC) aimed at reforming its pharmacy benefit management practices, particularly concerning insulin pricing. The FTC's allegations claimed that Caremark favored higher-cost insulin products to secure larger rebates, ultimately increasing costs for consumers. This settlement, announced on Tuesday, mandates that Caremark prioritize lower-cost drugs in its formularies and pass on savings negotiated with drug manufacturers to clients. The FTC estimates that these changes could save consumers up to $8.5 billion over the next decade, with an additional $4.5 billion in savings from rebates applied at the point of sale. The settlement aligns closely with a previous agreement made by Express Scripts, another major pharmacy benefit manager, while Optum Rx is still in negotiations with the FTC. The reforms are particularly crucial as Caremark, Express Scripts, and Optum Rx collectively manage around 80% of U.S. prescriptions, meaning their operational changes could significantly impact drug pricing and accessibility for millions of patients. The agreement also includes provisions to enhance transparency and prevent Caremark from obstructing independent pharmacies from collaborating with competing pharmacy hubs. Despite the anticipated consumer benefits, the settlement does not impose financial penalties on Caremark, and analysts suggest that the company, along with its peers, has already been moving towards rebate-free models in response to increasing regulatory scrutiny. CVS has expressed that this settlement allows them to focus on delivering value to consumers and employers while enhancing affordability and transparency in healthcare. The changes are expected to reshape the pharmacy benefits landscape, potentially alleviating some of the financial burdens faced by patients requiring essential medications like insulin.

Healthcare Dive · 1d ago

Disease & Epidemiology

All →

FTC Settles with CVS Caremark Over Insulin Price Manipulation, Promises Major Savings for Patients

The Federal Trade Commission (FTC) has reached a settlement with CVS Caremark, a leading pharmacy benefit manager, following allegations that the company manipulated insulin prices and obstructed patient access to this critical diabetes medication. The settlement is projected to save Americans approximately $8.5 billion in out-of-pocket expenses over the next decade. CVS Caremark, a subsidiary of CVS Health, is required to implement significant changes in its operations with employers, health plans, and pharmacies to enhance transparency and affordability. The FTC's complaint highlighted a troubling rebate system employed by CVS Caremark, along with competitors Cigna’s Express Scripts and UnitedHealth’s Optum Rx. This system reportedly favored insulin, leading to inflated list prices that ultimately burdened patients financially. The settlement aims to rectify these practices, with the FTC estimating an additional $4.5 billion in savings for patients through improved pharmacy counter rebates. This development is crucial for millions of Americans who rely on insulin for diabetes management, as it addresses systemic issues in drug pricing and access. The changes mandated by the FTC could set a precedent for how pharmacy benefit managers operate, potentially leading to more equitable pricing structures in the future. As the healthcare landscape evolves, stakeholders will be closely monitoring the implementation of these changes and their impact on patient care and affordability.

STAT News · 1d ago

U.S. Drug Discount Program Sees $100 Billion in Sales Amid Controversy

In 2025, sales from the 340B Drug Discount Program in the United States reached $100 billion, marking a significant 22.8% increase from the previous year, according to data from the Health Resources and Services Administration (HRSA). This program mandates that pharmaceutical companies provide substantial discounts, typically ranging from 25% to 50%, on outpatient drugs to hospitals and clinics that cater primarily to low-income patients. The rising sales figures highlight the growing reliance on expensive medications within the program, with high-cost drugs accounting for approximately $61.9 billion, or nearly 62% of total expenditures. Keytruda, an immunotherapy treatment developed by Merck, emerged as the most purchased drug under the program, with nearly $8.9 billion spent on it. Following closely was Biktarvy, an HIV medication from Gilead Sciences, which saw expenditures exceeding $4.47 billion. These figures underscore the increasing financial burden of high-cost therapies on the healthcare system, particularly for facilities serving vulnerable populations. The implications of these rising costs are significant for healthcare providers and policymakers, as they navigate the balance between ensuring access to essential medications and managing the financial sustainability of the 340B program. As the program continues to grow, stakeholders will need to address the challenges posed by escalating drug prices and their impact on healthcare delivery for low-income patients. The future of the 340B program may hinge on ongoing discussions about drug pricing reforms and the role of government in regulating pharmaceutical costs.

STAT News · 1d ago

Record Surge in Cyclospora Infections Linked to Lettuce in Michigan and Other States

In 2026, the U.S. is experiencing a record surge in cyclospora infections, with over 4,700 cases reported, surpassing the previous high in 2019. The CDC has confirmed 1,645 cases since May 1, with Michigan, Ohio, Kentucky, and West Virginia identified as states with linked outbreaks. Michigan alone has reported over 3,300 cases, prompting health officials to investigate lettuce and salad greens as potential sources. Natasha Bagdasarian, Michigan's chief medical executive, noted that interviews with patients frequently mentioned lettuce, leading to recommendations for consumers to avoid bagged products and wash whole heads of lettuce thoroughly. The cyclospora parasite causes watery diarrhea and is typically treated with antibiotics. Outbreaks are more common in warmer months, often linked to contaminated produce. The CDC has acknowledged that many cases may go unreported due to mild symptoms, and the true number of infections could be higher. Federal health officials are conducting traceback investigations on multiple produce items, but have not confirmed any specific food vendors as sources. Taco Bell has temporarily removed certain ingredients as a precaution, although the FDA has not directly implicated any specific restaurant. As the summer progresses, health officials expect case numbers to continue rising, with the CDC monitoring the situation closely. The increase in cyclospora cases may be attributed to better detection methods and climate change, which can affect the spread of foodborne illnesses. The public is urged to remain vigilant and follow health guidelines to minimize the risk of infection.

STAT News · 1d ago

Pharma & Medications

All →

CVS Caremark Settles with FTC, Promises Changes to Insulin Pricing Practices

CVS Health's Caremark has reached a significant settlement with the Federal Trade Commission (FTC) that mandates substantial changes to its pharmacy benefit management practices. This agreement, announced on Tuesday, addresses allegations that Caremark favored higher-priced insulin options to maximize rebates, consequently inflating costs for patients reliant on this essential diabetes medication. The FTC's lawsuit, filed in 2024, also targeted other major pharmacy benefit managers (PBMs) like Express Scripts and Optum Rx, with Express Scripts having already settled earlier this year. Under the terms of the settlement, Caremark is required to prioritize lower-cost medications on its formularies and ensure that savings negotiated with drug manufacturers are passed directly to clients. This includes a provision that allows patients' purchases through TrumpRx, an online drug marketplace, to count towards their deductibles in certain health plans once regulatory changes permit. Additionally, the settlement introduces measures aimed at enhancing transparency and preventing Caremark from obstructing independent pharmacies from collaborating with competing pharmacy hubs. FTC Chairman Andrew Ferguson emphasized that this settlement could lead to billions in savings for consumers facing high prescription drug prices, estimating a total of up to $8.5 billion in savings over the next decade. The reforms are particularly crucial as Caremark, along with Express Scripts and Optum Rx, controls approximately 80% of the U.S. prescription market, meaning changes in their practices could significantly impact patient costs and access to medications. Despite the anticipated benefits for consumers, the settlement does not impose financial penalties on Caremark, and analysts suggest that the PBMs may not see a decrease in profits. Instead, the settlements could help these companies avoid more severe regulatory actions in the future. CVS has expressed that this agreement allows them to focus on enhancing value for consumers and employers while promoting affordability and transparency in healthcare delivery.

BioPharma Dive · 1d ago

Clinical Research

All →

Supporting Early-Career Clinicians Amidst Workforce Challenges

The initial years of medical practice and research are critical for developing expertise and professional identity among early-career clinicians and academics. However, these formative years are increasingly fraught with challenges, including workforce pressures, staffing shortages, and funding constraints. Such conditions can hinder the growth and confidence of new professionals in the healthcare field. As universities and healthcare systems face mounting demands, it is essential to address these issues to ensure that early-career individuals receive the support they need to thrive. The healthcare community must prioritize initiatives that bolster the development of these professionals, ensuring a robust future workforce capable of meeting the evolving needs of patients and the healthcare system.

The Lancet · 1d ago

Health Policy

All →

California Lawmakers Propose Shield Laws to Protect Abortion Providers Amid Political Uncertainty

In response to the shifting political landscape surrounding abortion rights, California lawmakers are advancing legislation aimed at protecting healthcare providers who prescribe abortion medication and administer gender-affirming care from extradition requests. This move comes after Governor Gavin Newsom's refusal to extradite a physician accused of violating Louisiana's abortion laws, emphasizing California's commitment to reproductive rights. The proposed bill, spearheaded by Assembly member Rebecca Bauer-Kahan, seeks to ensure that future governors cannot unilaterally decide on extradition requests, thereby safeguarding providers from potential prosecution based on the political climate. The legislation is particularly significant in light of the Supreme Court's 2022 decision to overturn Roe v. Wade, which has led to a patchwork of abortion laws across the United States. Currently, 13 states have outright bans on abortion, while 28 others impose restrictions at various stages of pregnancy. As a result, many individuals in states with stringent abortion laws are increasingly relying on telehealth services to obtain abortion pills, with projections indicating a rise from 74,000 abortions in 2024 to 92,000 in 2025, according to the Guttmacher Institute. Supporters of the bill argue that it provides necessary protections for healthcare providers and patients, while opponents contend that it undermines the authority of states with stricter abortion laws. The debate reflects a broader national conflict between conservative and liberal states over reproductive rights. With the political stakes high, the outcome of this legislation could set a precedent for how states navigate the complex legal landscape surrounding abortion and healthcare. As California moves forward with this legislation, it joins a growing number of states that have enacted similar shield laws. However, the reliance on executive orders in some states raises concerns about the stability of these protections, especially if political leadership changes. The ongoing discussions highlight the urgent need for clear and consistent legal frameworks to protect reproductive rights across the country.

KFF Health News · 1d ago

Study Questions Efficacy of Arthroscopic Knee Surgery for Degenerative Cartilage Tears

A recent study published in the New England Journal of Medicine has raised significant concerns regarding the effectiveness of arthroscopic knee surgery for patients suffering from degenerative cartilage tears. Researchers tracked patients over a decade, comparing outcomes between those who underwent the surgery and those who received a sham procedure. The findings revealed that surgery not only provided minimal benefits but was also linked to increased pain and a higher likelihood of subsequent knee replacements. This study is particularly relevant for middle-aged and older adults experiencing knee pain, as it suggests that non-surgical interventions, such as physical therapy, may be more beneficial. The implications of this research are profound, as it challenges long-standing practices in orthopedic surgery. In Finland, the rate of arthroscopic knee surgeries has plummeted by 90%, while in the U.S., the decline has been more gradual, with a 4% annual decrease in meniscus surgeries from 2010 to 2020. Data from Medicare indicates a drop from 169,000 procedures in 2014 to an estimated 91,000 in 2024. This trend reflects a growing recognition of the ineffectiveness of surgery for degenerative conditions, which are often asymptomatic in older adults. Despite the evidence, opinions among orthopedic specialists vary. Some, like Robert Brophy from Washington University, acknowledge that while many patients do benefit from surgery, the current practice is inconsistent across regions. A consensus statement from orthopedic societies in Europe and the U.S. advocates for a trial of physical therapy before considering surgery, yet still supports surgical options. The Save the Meniscus Society continues to promote non-surgical treatments to preserve knee health. As the medical community grapples with these findings, the future of arthroscopic knee surgery remains uncertain. The financial implications of surgical procedures, influenced by the Relative Value Scale Update Committee, further complicate the decision-making process for physicians. With ongoing debates about the best treatment approaches, healthcare providers are urged to consider the latest evidence and prioritize patient outcomes over traditional practices.

KFF Health News · 1d ago

California's Medicaid Program Faces GOP Criticism Amid Support for Social Services

California's Medicaid program, known as Medi-Cal, is under scrutiny from Republican lawmakers, particularly Sen. John Kennedy of Louisiana, who has accused the state of misusing federal funds by providing housing and food assistance to low-income patients. Kennedy's claims highlight a growing partisan divide over the role of social services in healthcare, with Republicans arguing that such expenditures strain taxpayer resources, while Democrats, including Governor Gavin Newsom, defend these initiatives as essential for improving health outcomes and reducing long-term healthcare costs. Newsom emphasizes that investing in social services can prevent costly emergency room visits and hospitalizations, advocating for a 'whole-person care' approach. The debate has intensified as the Trump administration seeks to limit Medicaid spending on non-traditional healthcare services, potentially impacting millions of beneficiaries. Patients like Lucy Rodriguez, a 73-year-old Medi-Cal enrollee, have shared personal stories of how these services have significantly improved their quality of life, managing chronic conditions and alleviating financial stress. Rodriguez's experience underscores the potential consequences of proposed cuts to social services, which could leave vulnerable populations without necessary support. The Centers for Medicare & Medicaid Services (CMS) has indicated that future funding for social services will be evaluated on a case-by-case basis, raising concerns about the sustainability of current programs. As the political battle continues, healthcare policy researchers point out that a significant portion of health outcomes is influenced by social determinants, suggesting that investments in these areas could ultimately lead to better health for the Medicaid population. The ongoing conflict reflects broader national discussions about the future of Medicaid and the balance between healthcare and social services.

KFF Health News · 2d ago

Nutrition & Prevention

All →

CDC Addresses Ongoing Ebola Outbreak in DRC and Uganda as of July 2026

The Centers for Disease Control and Prevention (CDC) has issued a statement regarding the current Ebola outbreak affecting the Democratic Republic of Congo (DRC) and Uganda as of July 10, 2026. This outbreak has raised significant public health concerns due to the highly contagious nature of the Ebola virus and its potential for rapid transmission in affected regions. The CDC emphasizes the importance of monitoring and controlling the spread of the virus to prevent further outbreaks. Ebola, a severe and often fatal illness, has been a persistent threat in Central Africa, with the DRC and Uganda being particularly vulnerable due to their proximity to previous outbreaks and the challenges in healthcare infrastructure. The CDC's statement highlights the need for increased surveillance, vaccination efforts, and community engagement to mitigate the impact of the outbreak. Healthcare professionals and organizations are urged to remain vigilant and prepared for potential cases, as the situation continues to evolve. The CDC is collaborating with local health authorities and international partners to provide support and resources necessary for effective outbreak management. As the situation develops, further updates and guidance will be provided to ensure the safety and health of the populations at risk.

CDC Healthy Living · 5d ago